FIELD: medicine.
SUBSTANCE: invention refers to medicine and is aimed at treating inflammatory diseases associated with TNF-α. Proposed is a water composition containing 50 mg/ml of etanercept, 1.3mg/ml of aspartic acid as the aggregation inhibitor, 1.5 mg/ml of lysine as the aggregation inhibitor and the stabilizer, 1.5 mg/ml of single-substituted sodium phosphate, 3.3 mg/ml of secondary acidic potassium phosphate, 20 mg/ml of sucrose, 5.8 mg/ml of sodium chloride, 0.37 mg/ml of a disodium salt of EDTA (ethylene diamine tetraacetic acid), 0.1 mg/ml of polysorbate 20 at the pH of 6.3.
EFFECT: invention provides improved stability for a long period of time.
1 cl, 15 dwg, 12 tbl, 7 ex
Title | Year | Author | Number |
---|---|---|---|
STABLE PHARMACEUTICAL COMPOSITION OF TNFR: FC FUSION PROTEIN | 2013 |
|
RU2664691C2 |
FUSION PROTEIN PURIFICATION METHOD | 2015 |
|
RU2698654C2 |
STABLE LIQUID ETANERCEPT COMPOSITION | 2012 |
|
RU2575619C2 |
STABLE LIQUID PHARMACEUTICAL PREPARATIONS OF FUSED PROTEIN TNFR: Fc | 2012 |
|
RU2614257C2 |
LIQUID PHARMACEUTICAL COMPOSITION | 2015 |
|
RU2719431C2 |
ALTERNATIVE COMPOSITIONS FOR TNFR:FC CHIMERICAL POLYPEPTIDES | 2014 |
|
RU2663727C2 |
COMPOSITION OF CTLA-4 ANTIBODIES | 2006 |
|
RU2356579C1 |
VERSIONS OF PERTUZUMAB AND THEIR ANALYTICAL CHARACTERISTICS | 2014 |
|
RU2737727C2 |
QUANTITATIVE ESTIMATION OF MISFOLDED TNFR2:Fc | 2015 |
|
RU2698671C2 |
FLUID FORMULATION OF FOLLICLE-STIMULATING HORMONE | 2011 |
|
RU2553375C2 |
Authors
Dates
2016-10-27—Published
2011-05-04—Filed